This is a summary of the European public assessment report (EPAR) for Stribild. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Stribild. For practical information about using Stribild, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.
Therapeutic Area (MeSH)
N/AATC Code
J05AR09
ATC Item
emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Stribild
Medicine Name
Stribild
Aliases
N/ANo risk management plan link.
